Ask For Discount Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/1600
Strategic merger and acquisition amongst the companies to expand the market for anti-body
coupled T receptor therapy.
Unum Therapeutics is currently the only company that is working actively in anti-body coupled
T receptor therapy. It has several product in its pipeline, and they vary based on the
technology used for expression of receptor in patients T cell such as mRNA or viral vector.
There is also combination of different monoclonal antibodies to be used for coupling such as
rituximab, and trastuzumab. In phase one clinical trial, rituximab coupled t receptor therapy
found to produce desired therapeutic effects. Seattle Genetics, Inc. and Unum Therapeutics, Inc.
in 2015 entered into a strategic collaboration and license agreement to develop and
commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. This
collaboration would enable study of different combination of the tumor-specific monoclonal
antibodies with T receptor and cater to patient specific treatment needs.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com